Pharmacotherapy for Status Epilepticus
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Status epilepticus (SE) represents the most severe form of epilepsy. It is one of the most common neurologic emergencies, with an incidence of up to 61 per 100,000 per year and an estimated mortality of 20 %. Clinically, tonic-clonic convulsive SE is divided into four subsequent stages: early, established, refractory, and super-refractory. Pharmacotherapy of status epilepticus, especially of its later stages, represents an "evidence-free zone," due to a lack of high-quality, controlled trials to inform clinical decisions. This comprehensive narrative review focuses on the pharmacotherapy of SE, presented according to the four-staged approach outlined above, and providing pharmacological properties and efficacy/safety data for each antiepileptic drug according to the strength of scientific evidence from the available literature. Data sources included MEDLINE and back-tracking of references in pertinent studies. Intravenous lorazepam or intramuscular midazolam effectively control early SE in approximately 63-73 % of patients. Despite a suboptimal safety profile, intravenous phenytoin or phenobarbital are widely used treatments for established SE; alternatives include valproate, levetiracetam, and lacosamide. Anesthetics are widely used in refractory and super-refractory SE, despite the current lack of trials in this field. Data on alternative treatments in the later stages are limited. Valproate and levetiracetam represent safe and effective alternatives to phenobarbital and phenytoin for treatment of established SE persisting despite first-line treatment with benzodiazepines. To date there are no class I data to support recommendations for most antiepileptic drugs for established, refractory, and super-refractory SE. Limiting the methodologic heterogeneity across studies is required and high-class randomized, controlled trials to inform clinicians about the best treatment in established and refractory status are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trinka, E., Cock, H., Hesdorffer, D., Rossetti, A. O., Scheffer, I. E., Shinnar, S., Shorvon, S., & Lowenstein, D. H. (2015) · Epilepsia · doi:10.1111/epi.13121 · Cited by 2,494
Self-citationA Comparison of Four Treatments for Generalized Convulsive Status Epilepticus
Treiman, D. M., Meyers, P. D., Walton, N. Y., Collins, J. F., Colling, C., Rowan, A. J., Handforth, A., Faught, E., Calabrese, V. P., Uthman, B. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809173391202 · Cited by 1,325
Alldredge, B. K., Gelb, A. M., Isaacs, S. M., Corry, M. D., Allen, F., Ulrich, S., Gottwald, M. D., O'Neil, N., Neuhaus, J. M., Segal, M. R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa002141 · Cited by 888
It’s time to revise the definition of status epilepticus
Lowenstein, D. H., Bleck, T., & Macdonald, R. L. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb02000.x · Cited by 805 · cited 3×
“than 5 min [1].”
McIntyre, J., Robertson, S., Norris, E., Appleton, R., Whitehouse, W. P., Phillips, B., Martland, T., Berry, K., Collier, J., Smith, S., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66909-7 · Cited by 445
Double-blind study of lorazepam and diazepam in status epilepticus
Leppik, L. E. (1983) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1983.03330350028021 · Cited by 354
Lahat, E. (2000) · BMJ · doi:10.1136/bmj.321.7253.83 · Cited by 294 · cited 1×
“In three randomized, controlled trials comparing IN midazolam with IV diazepam, IN midazolam was equally effective as IV diazepam, with a lower mean time to control of seizures in the midazolam group than in the diazepam group, and no significant side effects observed in either group [59–61].”
A comparison of rectal diazepam gel and placebo for acute repetitive seizures
Dreifuss, F. E., Rosman, N. P., Cloyd, J. C., Pellock, J. M., Kuzniecky, R. I., Lo, W. D., Matsuo, F., Sharp, G. B., Conry, J. A., Bergen, D. C., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806253382602 · Cited by 287
Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children
Mahmoudian, T., & Mohammadi Zadeh, M. (2004) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2004.01.003 · Cited by 171 · cited 1×
“In three randomized, controlled trials comparing IN midazolam with IV diazepam, IN midazolam was equally effective as IV diazepam, with a lower mean time to control of seizures in the midazolam group than in the diazepam group, and no significant side effects observed in either group [59–61].”
Fişgin, T., Gurer, Y., Tezic, T., Senbil, N., Zorlu, P., Okuyaz, C., & Akgün, D. (2002) · Journal of Child Neurology · doi:10.1177/088307380201700206 · Cited by 138 · cited 1×
“In addition, IN midazolam was found to be more effective than rectal diazepam in children with prolonged convulsive seizures, without serious complications [62].”
Background
Cited by
Kienitz, R., Kay, L., Beuchat, I., Gelhard, S., von Brauchitsch, S., Mann, C., Lucaciu, A., Schäfer, J.-H., Siebenbrodt, K., Zöllner, J.-P., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00940-2 · Cited by 139
“Here, the comparably long half-life of DZP especially stands out [181].”
Background
Metadata
- Authors
- Trinka, E., Höfler, J., Leitinger, M., & Brigo, F.
- Venue
- Drugs
- Published
- 2015-08-27
- Volume
- 75
- Issue
- 13
- Pages
- 1499-1521
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W1946056514
- Cited by
- 208
- References
- 13
- FWCI
- 15.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacotherapy for Status Epilepticus. https://app.cochat.ai/papers/10.1007/s40265-015-0454-2
- The paper
- Trinka, E., Höfler, J., Leitinger, M., & Brigo, F. (2015). Pharmacotherapy for Status Epilepticus. Drugs. https://doi.org/10.1007/s40265-015-0454-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.